{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133209","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.256497+00:00","generated_at":"2026-06-02T18:39:43.971918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DBV Technologies reports Q1 net loss $27.3M; cash runway only through Dec 2024, substantial doubt","bullets":["Cash & equivalents $101.5M as of March 31, down from $141.4M at Dec 31, 2023.","Net loss of $27.3M ($0.28 per share) vs $20.6M loss in Q1 2023, driven by R&D spending on VITESSE.","Operating cash burn $34.7M in Q1 2024; company warns cash insufficient for 12 months, requires additional capital.","VITESSE Phase 3 enrollment on track to screen last patient by Q3 2024; 86 sites in US, Canada, Europe, UK, Australia.","Appointed Robert Pietrusko as Chief Regulatory Officer; he led over 35 BLA/NDA/MAA approvals globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133209","json":"https://secwatch.observer/filing/0001193125-24-133209.json","markdown":"https://secwatch.observer/filing/0001193125-24-133209.md","text":"https://secwatch.observer/filing/0001193125-24-133209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524133209/0001193125-24-133209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524133209/d833388d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:39:43.971918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b34a169534b7ca7d81e79dd3b89d55183ef3c621","claim":"DBV Technologies S.A. reported the first quarter ended March 31, 2024 results: net income (27,3), EPS (0,28).","evidence_excerpt":"DBV Technologies Reports First Quarter 2024 Financial Results and Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524133209/0001193125-24-133209-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"(27,3)"},{"label":"EPS","value":"(0,28)"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}